Martin Shkreli, the former drug firm executive who ordered dramatic price hikes of Daraprim (Pyrimethamine), an anti-parasitic medicine, has been barred from the pharma industry for life. A US federal judge ordered him to repay $64.6m (£47m) in profits he made from the scheme, ruling that his actions had violated laws against monopolies. Shkreli is currently serving a prison sentence for defrauding investors.
Green Tea Daily Wards Off Influenza And Other Respiratory Viruses, Say Researchers